Edgar Filing: ANTIGENICS INC /DE/ - Form 4

ANTIGEN	ICS INC /DE/										
Form 4											
July 03, 20	07										
FORM	// //	~ ~							OMB APPROVAL		
UNITED STATES SECURITIES AND EXCH Washington, D.C. 2054							COMMISSION	NOMB Number:	3235-0287		
	this box										
if no lo subject		MENT OF	F CHAN		Expires: Estimated	2005 average					
Section	16.			SECUI	burden ho						
Form 4					~ .	response	. 0.5				
Form 5 obligati	incu pu						nge Act of 1934,				
may co							of 1935 or Section	on			
<i>See</i> Inst 1(b).	truction	30(h)	of the I	nvestmen	t Compar	ny Act of 1	940				
(Print or Type	e Responses)										
	Address of Reporting	Person [*]	2. Issuer Name and Ticker or Trading			-	of Reporting Per	Reporting Person(s) to			
JORDAN WADIH			Symbol				Issuer				
			ANTIGENICS INC /DE/ [AGEN]				(Check all applicable)				
(Last) (First) (Middle)			3. Date of	of Earliest T	ransaction						
			(Month/Day/Year)				X_ Director 10% Owner				
298 FREEMANS LN.			07/02/2	2007			Officer (give title below) Other (specify below)				
(Street)			4. If Amendment, Date Original			6. Individual or Joint/Group Filing(Check					
				onth/Day/Yea	-		Applicable Line)				
							X Form filed by				
FRANKLI	N LAKES, NJ 07	417					Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Securities A	cquired, Disposed o	of, or Beneficia	ally Owned		
1.Title of	2. Transaction Date			3.	4. Securit			6. Ownership	7. Nature of		
Security (Instr. 3)	(Month/Day/Year)	Execution any	Date, 1f	Transactic Code	nAcquired (A) or Disposed of (D)			Form: Direct (D) or Indirect	Indirect Beneficial		
(111501. 5)		(Month/Da	y/Year)	(Instr. 8)	(Instr. 3, 4		· · · ·	(I)	Ownership		
						,		(Instr. 4)	(Instr. 4)		
						(A)	Reported				
						or	Transaction(s) (Instr. 3 and 4)				
				Code V	Amount	(D) Price	(
Reminder: Re	eport on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly of	or indirectly.				
							spond to the colle		SEC 1474		
							ained in this form ond unless the for		(9-02)		
					•	-	ntly valid OMB co				
					numb	er.					

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A) or		

Edgar Filing: ANTIGENICS INC /DE/ - Form 4

Derivative Security			Disposed of (D) (Instr. 3, 4, and 5)							
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Shares (1)	<u>(1)</u>	07/02/2007	А		3,395.102		<u>(1)</u>	<u>(1)</u>	Common Stock	3,395.102

Reporting Owners

Reporting Owner Name / Address		Relationsh	ips				
	Director	10% Owner	Officer	Other			
JORDAN WADIH 298 FREEMANS LN. FRANKLIN LAKES, NJ 07417	Х						
Signatures							
Christine M. Klaskin, by Power Attorney	of	07/0	3/2007				
**Signature of Reporting Person		D	ate				
Explanation of Responses:							

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Acquired under the Antigenics Inc. Directors' Deferred Compensation Plan. Deferred shares represent an equal amount of shares of the (1) Company's common stock to be distributed with the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.